Seattle / Boston / Berlin / Sitges / Francisco San Francisco / Chicago / /
Company
Merck & Co. Inc. / Gilead Sciences Inc. / Yukl SA / CCR5 / Balazs AB / AIDS Clinical Trials Group / Gunthard HF / PRINTER-FRIENDLY VERSION AVAILABLE AT IDSE.NET / /
Continent
North America / Europe / /
Country
United States / Australia / Spain / /
Event
FDA Phase / Judicial Event / /
Facility
Medicine University of California / /
IndustryTerm
immune systems / Prevention of HIV / intima-media thickness / HIV prevention / reservoir site / treatment of HIV / research / treatment of cancer / /
MedicalCondition
inflammatory response / hypertensive heart disease / advanced human immunodeficiency virus infection / simian AIDS / HIV / epidemic / HIV RNA / myocardial fibrosis / low-level viremia / low-level residual viremia / acute/early HIV infection / MS / liver disease / lymphatic tissue fibrosis / Gut-associated lymphoid tissue fibrosis / treated HIV infection / osteopenia / fibrotic and inflammatory contributions / persistent low-level viremia / ht Co rig TO INFECTION / serious diseases / cancer / Opportunistic Infections / plasma viremia / disease / atherosclerosis / lymphoid fibrosis / viremia / end-stage organ disease / Latent infection / reversible immune dysfunction / AIDS / infection / chronic infection / acute myelogenous leukemia / Inflammatory / /
MedicalTreatment
adoptive transfer / adjunctive therapies / antiretroviral therapy / highly active antiretroviral therapy / chemotherapy / HAART / total body irradiation / chemoprophylaxis / /
NaturalFeature
Indies / /
Organization
Administration of Vorinostat / University of California at San Francisco / CD28 / /
Person
HIV HIROYU HATANO / Bailey JR / Lama JR / at expanding HIV-specific responses / /
Position
Walker / rt / FUNCTIONAL CURE MODEL / Mitsuyasu RT / Assistant Professor / Porter / animal model / Gandhi RT / /
Product
telmisartan / lisinopril / Captopril / CD4 / /
ProvinceOrState
Illinois / Washington / California / Massachusetts / /
PublishedMedium
PLoS Medicine / Antimicrobial Agents and Chemotherapy / PLoS One / /
PRINTER-FRIENDLY VERSION AVAILABLE AT IDSE.NET Novel Approaches To Curing HIV HIROYU HATANO, MD, MHS ll